Led · Seed · Jul 2026

Inner Logic develops a simulation and data platform that allows device manufacturers to design, test, and validate procedural devices across thousands of virtual patients grounded in real clinical and procedural data. The company’s infrastructure aims to shift exploratory device development from physical prototypes and cadaver labs into in silico testing to accelerate iteration and broaden patient coverage. Founders include CEO Tito Porras, MD; CTO Mathias Unberath, PhD; and Chief Robotics Officer Axel Krieger, PhD, who collectively have authored over 400 peer-reviewed publications and are named inventors on more than 40 patents. Inner Logic has demonstrated its technology by training AI in simulation for orthopedic trauma and deploying it successfully on real hardware and patient anatomy, and by completing key steps of an autonomous gallbladder removal in a live animal model. The company is positioning its platform to support the development and validation of intelligent and autonomous procedural systems as they move toward clinical deployment. The announced financial position includes an $11.5 million seed round to advance product development and scaling.

Led · Seed · Mar 2026

Great Sky builds a computing architecture that integrates superconducting computation, high-bandwidth optical connectivity, and semiconductor circuitry to enable brain-like, low-latency, energy-efficient AI processing. The team traces its work to 12 years of research at the U.S. National Institute of Standards and Technology, producing 23 peer-reviewed publications and eight patents. Its first-generation chips have completed tape-outs and the company reports integration of components into complete neural networks, with claimed performance such as processing over 60 million video frames per second in video-analysis scenarios. Great Sky plans to manufacture its technology in scalable processes and pursue multi-modular cognitive systems by tiling wafer-scale networks with advanced fiber-optic interconnection. Financially, the company disclosed a $14 million seed round led by Bison Ventures to support these development and commercialization efforts. The company was founded by CEO Jeff Shainline, CTO Jeff Chiles, VP of Fabrication Saeed Khan, and VP of Architecture Bryce Primavera.

Led · Series A · Jan 2026

Founded in 2024, Grid Aero designs and manufactures uncrewed, ultra-simple airframes paired with advanced autonomous systems, enabling thousands of pounds of cargo to be flown thousands of miles from austere or degraded locations. The company’s flagship platform, the Lifter Lite, targets defense ‘contested logistics’ missions but is also attracting commercial and humanitarian interest through partnerships with Everts Air and Aviation Without Borders. By offering scalable, persistent logistics and sensing capabilities at a fraction of the cost of legacy systems, Grid Aero aims to build a smarter, distributed global logistics network. The newly raised capital will transition Lifter Lite from prototype testing to operational deployments and major exercises. Grid Aero emphasizes speed of execution, having built and flown its aircraft in less than 18 months. While specific revenue or user metrics were not disclosed, the company highlights growing demand across defense, remote, and humanitarian sectors. The Series A funding underscores investor confidence in Grid Aero’s ability to rapidly field autonomous airlift solutions.

Led · Series B · Jan 2026

Juvena Therapeutics leverages artificial intelligence and insights from human stem cell biology to engineer first-in-class regenerative biologics aimed at reversing tissue degeneration. Its lead candidate, JUV-161, is in Phase 1 studies and has shown preclinical benefits in myogenesis, muscle metabolism, and strength for myopathic conditions; dosing is complete in five of six SAD cohorts and all MAD cohorts with study completion expected by January. The company recently signed a research and collaboration agreement with Eli Lilly worth more than $650 million in potential milestones, underscoring the commercial interest in its platform. Proceeds from the latest financing will fund advancement of JUV-161, expansion of its pipeline targeting neuromuscular and age-related diseases, and further development of its AI discovery capabilities. Juvena is also pursuing additional partnership opportunities and has launched a search for a new CEO as it scales. Headquartered in Redwood City, California, the company has expanded its board and clinical leadership team to support its next phase of growth. No revenue or user metrics have been disclosed, but the company positions itself as a leader in regenerative medicine.

Led · Series A · Dec 2025

Allonnia develops selective separation solutions that enable industrial customers to eliminate pollutants and upgrade mineral resources. Its portfolio includes SAFF®, which targets PFAS treatment, and Allonnia D-Solve, a recyclable biosolution that dissolves gangue minerals to deliver cleaner, higher-value concentrates. The company is positioning D-Solve as a key tool for miners striving to improve critical-mineral recovery while reducing environmental impact. Led by CEO Nicole Richards, Allonnia plans to pilot D-Solve at its first mine site and scale commercial deployments. The firm describes its capabilities as “bio-ingenuity,” combining biology and engineering to solve complex environmental challenges. Following the latest financing, Allonnia’s total capital raised exceeds $100 million, giving it resources to accelerate go-to-market efforts and expand its technology stack.